GO
Loading...

Biogen Idec Inc

More

  • July 23- Biogen Idec Inc reported sharply higher-than-expected quarterly revenue on surging sales of its new Tecfidera treatment for multiple sclerosis, and the company raised its full-year profit forecast. U.S. sales of $585 million blew past Wall Street expectations in the $485 million range.

  • Biogen revenue trounces forecast as MS drug sales surge Wednesday, 23 Jul 2014 | 7:04 AM ET

    July 23- Biogen Idec Inc reported sharply higher-than-expected quarterly revenue on surging sales of its new Tecfidera oral treatment for multiple sclerosis, and the company raised its full-year profit forecast. The company on Wednesday said it had earned $723.1 million, or $3.01 per share, in the second quarter.

  • Politics fade as earnings take over Friday, 18 Jul 2014 | 6:30 PM ET
    Espirito Santo International is the parent company of several institutions, including Banco Espirito Santo.

    Even as traders monitor the world's hot spots, corporate earnings news could be a positive for stocks in the week ahead.

  • UPDATE 2-Gambro acquisition boosts Baxter's sales Thursday, 17 Jul 2014 | 1:30 PM ET

    July 17- Medical device and drug maker Baxter International Inc reported higher-than-expected quarterly adjusted earnings, driven primarily by a surge in sales of the dialysis products it gained from its acquisition of Gambro AB last year.

  • The Alzheimer's epidemic: Where we stand Friday, 11 Jul 2014 | 11:45 AM ET

    Although treatments for Alzheimer's have struggled, drugmakers are still working in the space, with 67 medicines currently in development.

  • Cramer: 4 strong stocks for months to come Wednesday, 9 Jul 2014 | 6:29 PM ET

    If the charts are to be believed, the path of least resistance for these 4 stocks should be higher.

  • Cramer: Six buyable themes in second half Tuesday, 1 Jul 2014 | 6:08 PM ET
    Jim Cramer on Mad Money.

    Cramer says the price action in Tuesday’s market is sending an important message about what to buy in the days ahead.

  • Dow's 7 underperformers—time to buy? Tuesday, 24 Jun 2014 | 8:52 AM ET
    Nike sneakers sit on display at a Foot Locker store inside the South Park Mall in Strongsville, Ohio, March 4, 2014.

    Of the 30 stocks on the Dow, only seven have not hit 52-week highs this year. Is it time to bet on these underperformers?

  • Aging stinks, so at least make some money from it Monday, 23 Jun 2014 | 8:00 AM ET

    The US population is getting grayer, and while getting old stinks, there are plenty of ways to profit from an aging demographic using ETFs.

  • *Shire expecting to receive approaches, taps Citi- sources. LONDON, June 17- Shares in Shire hit a record high on Tuesday on expectations of a takeover as dealmaking sweeps the drugs sector, after Reuters reported the group had hired investment bank Citi as a defence adviser. Shire and Citi declined to comment.

  • Shire braces for takeover bids, hires Citi: Sources Monday, 16 Jun 2014 | 2:25 PM ET
    Ten milligram tablets of the hyperactivity drug, Adderall, made by Shire Plc.

    Shire has hired investment bank Citi as an adviser following a wave of deals in the healthcare sector.

  • Midday movers: Medtronic, Netflix, Tesla Motors & More Monday, 16 Jun 2014 | 12:12 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Monday's midday movers:

  • June 16- A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec and AbbVie Inc, but serious infections and potential liver toxicity continued to cloud the drug's future.

  • WASHINGTON, June 6- The U.S. Food and Drug Administration said on Friday it approved Biogen Idec Inc's long-lasting hemophilia A drug, Eloctate, adding another product to the company's nascent portfolio of drugs for non-malignant blood disorders. The FDA's ruling followed its approval in March of Biogen's hemophilia B treatment, Alprolix.

  • Midday movers: Apple, Astrotech, Blackberry & More Thursday, 29 May 2014 | 12:20 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of Thursday's midday movers:

  • ANALYSIS-Pfizer-AstraZeneca deal not quite dead yet Monday, 19 May 2014 | 6:36 PM ET

    NEW YORK, May 19- Pfizer Inc may have called its $118 billion bid for AstraZeneca Plc a "final" offer, and its British rival sees no prospect of a deal being revived. Morningstar analyst Damien Conover in Chicago said the odds of an AstraZeneca purchase had fallen well below the 50 percent mark.

  • Midday movers: NFLX, PCLN, BIIB & more Thursday, 15 May 2014 | 12:23 PM ET
    NYSE exchange floor

    Take a look at some of Thursday's midday movers:

  • UPDATE 1-Merck KGaA ekes out profit growth on cost cuts Thursday, 15 May 2014 | 2:56 AM ET

    FRANKFURT, May 15- Germany's Merck KGaA, the world's largest maker of liquid crystals for display screens, said quarterly underlying core earnings edged 0.7 percent higher as lower costs outweighed the impact of weak foreign exchange rates and sluggish growth in drugs sales.

  • *Hillshire to buy Pinnacle Foods for $6.6 billion. Biogen Idec jumped 4.8 percent to $300.54 and TripAdvisor Inc rose 5.8 percent to $89.51. Twitter gained 5.9 percent to $33.94 after news reports that brokerage SunTrust raised its rating on the stock to "buy."

  • *Hillshire to buy Pinnacle Foods for $6.6 billion. Biogen Idec jumped 4.8 percent to $300.54 and TripAdvisor Inc rose 5.8 percent to $89.51. Now people are trying to pick up bargains, and some of those stocks have been going up, "said Giri Cherukuri, head trader at OakBrook Investments LLC in Lisle, Illinois.